Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William G Wierda

Showing results (11-20 of 350) with videos related to

Pageof 35
Sort By:
Blood|February 21, 2020
How I manage CLL with venetoclax-based treatmentsWilliam G Wierda, Francesco Paolo Tambaro
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?Jennifer R Brown, William G Wierda
Frontiers in Oncology|May 31, 2021
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell MalignanciesHussein A Abbas, William G Wierda
Current Treatment Options in Oncology|May 5, 2005
Genetics and molecular biology of chronic lymphocytic leukemiaDennis A Carney, William G Wierda
Seminars in Hematology|April 15, 2026
Developing MRD as an early endpoint for accelerated approval in CLLJacob D Soumerai, William G Wierda
Best Practice & Research. Clinical Haematology|August 21, 2007
Gene therapy and active immune therapy of hematologic malignanciesWilliam G Wierda, Thomas J Kipps
Drugs|July 18, 2019
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic MalignanciesFevzi F Yalniz, William G Wierda
Seminars in Oncology|April 18, 2006
Initial therapy for patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan M O'Brien
Leukemia & Lymphoma|September 17, 2004
Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapyMichael E Rytting, William G Wierda
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2010
Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemiaSameer A Parikh, William G Wierda
Pageof 35

Showing results (11-20 of 350) with videos related to

Sort By:
Pageof 35
Blood|February 21, 2020
How I manage CLL with venetoclax-based treatmentsWilliam G Wierda, Francesco Paolo Tambaro
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?Jennifer R Brown, William G Wierda
Frontiers in Oncology|May 31, 2021
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell MalignanciesHussein A Abbas, William G Wierda
Current Treatment Options in Oncology|May 5, 2005
Genetics and molecular biology of chronic lymphocytic leukemiaDennis A Carney, William G Wierda
Seminars in Hematology|April 15, 2026
Developing MRD as an early endpoint for accelerated approval in CLLJacob D Soumerai, William G Wierda
Best Practice & Research. Clinical Haematology|August 21, 2007
Gene therapy and active immune therapy of hematologic malignanciesWilliam G Wierda, Thomas J Kipps
Drugs|July 18, 2019
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic MalignanciesFevzi F Yalniz, William G Wierda
Seminars in Oncology|April 18, 2006
Initial therapy for patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan M O'Brien
Leukemia & Lymphoma|September 17, 2004
Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapyMichael E Rytting, William G Wierda
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2010
Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemiaSameer A Parikh, William G Wierda
Pageof 35